Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entera BioENTX +2.66%28 3-1 Month Momentum % is 32.40% as of Aug. 13, 2026. GuruFocus rates ENTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,389 Biotechnology companies, Entera Bio ranks better than 91.14% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-13), Entera Bio's 3-1 Month Momentum % is 32.40%.
The industry rank for Entera Bio's 3-1 Month Momentum % or its related term are showing as below:
ENTX's 3-1 Month Momentum % is ranked better than 91.14% of 1389
companies
in the Biotechnology industry
Industry Median: -6.37
vs ENTX: 32.40
Entera Bio (NAS:ENTX) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Entera Bio 3-1 Month Momentum % Related Terms
ENTX vs ICCC, BDTX, COYA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Entera Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Entera Bio's 3-1 Month Momentum % falls into.
Entera Bio (NAS:ENTX) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio (ENTX) has a 3-1 Month Momentum % of 32.40% as of Aug. 13, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Entera Bio and its competitors. According to the industry distribution chart, Entera Bio ranks #123 out of 1389 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Entera Bio's 3-1 Month Momentum % too high?
Entera Bio's current 3-1 Month Momentum % is 32.40%. Based on the distribution chart, Entera Bio ranks #123 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Entera Bio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's 3-1 Month Momentum % compare to ICCC and BDTX?
According to the Biotechnology industry distribution chart, Entera Bio ranks #123 out of 1389 companies for 3-1 Month Momentum %. This places Entera Bio in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Entera Bio and its competitors. Entera Bio's current 3-1 Month Momentum % is 32.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current 3-1 Month Momentum % of 32.40%. The current 3-1 Month Momentum % is 32.40%. Entera Bio's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Entera Bio (ENTX), the current 3-1 Month Momentum % is 32.40% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
28GF Score
Get the complete analysis for ENTX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTX has been successfully added to your 
